Geneuro: presentation of new Temelimab data

(CercleFinance.com) - GeNeuro announces that new findings on the anti-neurodegenerative effect of Temelimab in an MS model were presented as a poster at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Congress in Copenhagen, Denmark.


The new data presented demonstrate that Temelimab repairs HERV-W ENV-mediated effects in mice expressing the HERV-W ENV envelope protein.

When transgenic animals are treated with an anti-HERV-W ENV antibody (mAb ENV01, the mouse equivalent of Temelimab), demyelination, neurodegeneration as well as microglial and astroglial polarization are repaired', says the group.

These results validate the mechanism of action that explains the promising clinical data GeNeuro has generated on key MRI and fluid biomarkers of neurodegeneration in over 300 MS patients. Despite the challenging circumstances currently facing the company, we remain committed to partnering to further develop Temelimab in MS, with a focus on disease progression - the major unmet medical need in MS today. said Jesús Martin Garcia, CEO of GeNeuro.

Copyright (c) 2024 CercleFinance.com. All rights reserved.